{"id":70275,"date":"2026-04-13T16:09:43","date_gmt":"2026-04-13T10:39:43","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70275"},"modified":"2026-04-13T16:09:45","modified_gmt":"2026-04-13T10:39:45","slug":"divi-laboratories-share-price-falls","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/","title":{"rendered":"Divi Laboratories Share Price Falls \u2014 What Investors Need to Know"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/\">Divi&#8217;s Laboratories \u2014 India&#8217;s most respected API manufacturer and the<\/a><\/p><p>[Click Here \u2013 Get Free Investment Predictions on Univest]<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#What_Triggered_the_Fall_%E2%80%94_Key_Details\" title=\"What Triggered the Fall \u2014 Key Details\">What Triggered the Fall \u2014 Key Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Why_the_Market_Is_Selling_Divi_Laboratories_Today\" title=\"Why the Market Is Selling Divi Laboratories Today\">Why the Market Is Selling Divi Laboratories Today<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#The_Bull_Case_%E2%80%94_Why_This_Sell-Off_May_Be_Overdone\" title=\"The Bull Case \u2014 Why This Sell-Off May Be Overdone\">The Bull Case \u2014 Why This Sell-Off May Be Overdone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#What_Most_Investors_Are_Missing\" title=\"What Most Investors Are Missing\">What Most Investors Are Missing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Divi_s_Laboratories_Share_Price_Levels_Support_2026_Target\" title=\"Divi s Laboratories Share Price: Levels, Support &amp; 2026 Target\">Divi s Laboratories Share Price: Levels, Support &amp; 2026 Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#The_Three_Scenarios_Investors_Are_Pricing_In_Right_Now\" title=\"The Three Scenarios Investors Are Pricing In Right Now\">The Three Scenarios Investors Are Pricing In Right Now<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Key_Business_Segments_What_to_Watch\" title=\"Key Business Segments &amp; What to Watch\">Key Business Segments &amp; What to Watch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#What_Should_Divi_Laboratories_Shareholders_Do_Today\" title=\"What Should Divi Laboratories Shareholders Do Today?\">What Should Divi Laboratories Shareholders Do Today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Frequently_Asked_Questions_People_Also_Ask\" title=\"Frequently Asked Questions (People Also Ask)\">Frequently Asked Questions (People Also Ask)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q1_Why_did_Divis_Labs_share_price_fall_today\" title=\"Q1. Why did Divi&#8217;s Labs share price fall today?\">Q1. Why did Divi&#8217;s Labs share price fall today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q2_What_is_DXM_and_why_does_it_matter_for_Divis\" title=\"Q2. What is DXM and why does it matter for Divi&#8217;s?\">Q2. What is DXM and why does it matter for Divi&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q3_Is_Divis_Labs_a_buy_after_todays_fall\" title=\"Q3. Is Divi&#8217;s Labs a buy after today&#8217;s fall?\">Q3. Is Divi&#8217;s Labs a buy after today&#8217;s fall?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q4_What_is_Divis_Labs_share_price_target_2026\" title=\"Q4. What is Divi&#8217;s Labs share price target 2026?\">Q4. What is Divi&#8217;s Labs share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q5_What_is_CDMO_and_why_is_it_important_for_Divis\" title=\"Q5. What is CDMO and why is it important for Divi&#8217;s?\">Q5. What is CDMO and why is it important for Divi&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q6_How_did_Chinese_overcapacity_affect_Divis_before\" title=\"Q6. How did Chinese overcapacity affect Divi&#8217;s before?\">Q6. How did Chinese overcapacity affect Divi&#8217;s before?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q7_What_is_Divis_competitive_advantage_in_APIs\" title=\"Q7. What is Divi&#8217;s competitive advantage in APIs?\">Q7. What is Divi&#8217;s competitive advantage in APIs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Q8_What_should_long-term_Divis_investors_do\" title=\"Q8. What should long-term Divi&#8217;s investors do?\">Q8. What should long-term Divi&#8217;s investors do?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/divi-laboratories-share-price-falls\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Triggered_the_Fall_%E2%80%94_Key_Details\"><\/span><strong>What Triggered the Fall \u2014 Key Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Detail<\/strong><\/td><\/tr><tr><td>Trigger<\/td><td>Dextromethorphan (DXM) API global<\/td><\/tr><tr><td>price falls 22% QoQ on Chinese<\/td><td>capacity addition<\/td><\/tr><tr><td>DXM Revenue (Divi&#8217;s)<\/td><td>Approximately Rs 800 Cr annually \u2014<\/td><\/tr><tr><td>Chinese API Overcapacity<\/td><td>4 new large-scale Chinese<\/td><\/tr><tr><td>dextromethorphan plants<\/td><td>commissioned in 6 months<\/td><\/tr><tr><td>Divi&#8217;s Q4 FY26 Margin<\/td><td>EBITDA margin 33.8% \u2014 below 36% in<\/td><\/tr><tr><td>Naproxen Pricing<\/td><td>Naproxen (another key API) also<\/td><\/tr><tr><td>CDMO Revenue<\/td><td>Rs 320 Cr in Q4 FY26 \u2014 growing but<\/td><\/tr><tr><td>Management Guidance<\/td><td>&#8216;API price normalisation expected<\/td><\/tr><tr><td>by Q2 FY27 as Chinese inventory<\/td><td>clears&#8217;<\/td><\/tr><\/tbody><\/table><\/figure><p><em>Source: Company filings, exchange announcements, analyst reports.<\/em><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_the_Market_Is_Selling_Divi_Laboratories_Today\"><\/span><strong>Why the Market Is Selling Divi Laboratories Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s fell 5.3% as the global price of Dextromethorphan (DXM) \u2014 one of its key APIs \u2014 fell 22% due to new Chinese manufacturing capacity additions. DXM contributes approximately Rs 800 crore in annual revenue. Combined with Naproxen&#8217;s 8% price decline, Divi&#8217;s Q4 EBITDA margin compressed to 33.8% from 36% year-on-year.<\/p><p><a href=\"https:\/\/univest.in\/\">[Tap to Access Best Research Pieces on Univest]<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Bull_Case_%E2%80%94_Why_This_Sell-Off_May_Be_Overdone\"><\/span><strong>The Bull Case \u2014 Why This Sell-Off May Be Overdone<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s at Rs 4,050 and 34% below its peak offers entry into India&#8217;s best API manufacturer at a meaningful discount. The API price cycle is historically 2\u20134 quarters. The CDMO business is structurally immune to commodity pricing. Consult a SEBI-registered financial advisor before investing.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Most_Investors_Are_Missing\"><\/span><strong>What Most Investors Are Missing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s at Rs 4,050 \u2014 approaching its 52-week low of Rs 3,800 \u2014 is the most debated pharma stock in the current market. At 52x P\/E on depressed FY26 earnings, the stock appears expensive. At 28\u201330x FY28 earnings (when CDMO reaches Rs 1,500 crore and APIs partially recover), it appears cheap. The Rs 3,800 level is the technical anchor. Investors who<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Divi_s_Laboratories_Share_Price_Levels_Support_2026_Target\"><\/span><strong>Divi s Laboratories Share Price: Levels, Support &amp; 2026 Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 4,050<\/td><td>52-Week High<\/td><td>Rs 6,200<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 3,800<\/td><td>Decline from Peak<\/td><td>34%<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 1.1L Cr<\/td><td>Trailing P\/E<\/td><td>52x<\/td><\/tr><tr><td>Short-Term Support<\/td><td>Rs 3,800\u20133,950<\/td><td>Short-Term Resistance<\/td><td>Rs 4,400\u20134,700<\/td><\/tr><tr><td>NSE Symbol<\/td><td>DIVISLAB<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><\/tr><\/tbody><\/table><\/figure><p><em>Data sourced from NSE, BSE, and analyst consensus reports. For informational purposes only.<\/em><\/p><p>[Download the Univest App to track Divi s Laboratories live with SEBI-registered research alerts]<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Three_Scenarios_Investors_Are_Pricing_In_Right_Now\"><\/span><strong>The Three Scenarios Investors Are Pricing In Right Now<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>What It Means for Investors<\/strong><\/td><\/tr><tr><td>BEAR<\/td><td>Macro deterioration and continued sector pressure push Divi s Laboratories toward support at , threatening a further 10-15% decline from current levels.<\/td><\/tr><tr><td>BASE<\/td><td>Stabilization near 52-Week High&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rs 6,200 followed by a gradual earnings recovery drives the stock back toward&nbsp; over the next 12 months.<\/td><\/tr><tr><td>BULL<\/td><td>A beat-and-raise quarter with improved guidance triggers a sharp re-rating toward analyst targets of Short-Term Support&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rs 3,800\u20133,950, representing 20-30% upside from current levels.<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Business_Segments_What_to_Watch\"><\/span><strong>Key Business Segments &amp; What to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Analyst consensus 12-month Divi&#8217;s target is Rs 5,000\u20135,800. The stock trades at Rs 4,050, implying 23\u201343% upside. DXM price recovery and CDMO order book expansion are the primary catalysts. These are analyst estimates, not guaranteed returns.<\/p><p><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">[Track Divi s Laboratories and sector peers live on the Univest Screener \u2014 real-time fundamentals, FII\/DII flows, and analyst ratings]<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Should_Divi_Laboratories_Shareholders_Do_Today\"><\/span><strong>What Should Divi Laboratories Shareholders Do Today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s at Rs 4,050 \u2014 approaching its 52-week low of Rs 3,800 \u2014 is the most debated pharma stock in the current market. At 52x P\/E on depressed FY26 earnings, the stock appears expensive. At 28\u201330x FY28 earnings (when CDMO reaches Rs 1,500 crore and APIs partially recover), it appears cheap. The Rs 3,800 level is the technical anchor.<\/p><p>Investors who believe the API price cycle is 2\u20134 quarters, not structural, should find this range attractive. Divi&#8217;s Laboratories \u2014 entry, stop-loss, and target.<\/p><p>[Subscribe to Univest Pro for SEBI-registered analyst recommendations \u2014 entry, stop-loss, and target]<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Divi&#8217;s 5.3% fall on API price data is a legitimate concern in a stock priced for premium compounding. DXM&#8217;s 22% price decline is painful but follows the classic Chinese overcapacity cycle that Divi&#8217;s has navigated before.<\/p><p>The CDMO business \u2014 structurally immune to spot API pricing \u2014 is the quality growth engine that the market is discounting alongside the commodity API business. Rs 3,800 is the 52-week low. Q2 FY27 DXM price data and CDMO order announcements are the resolution catalysts.<\/p><p>Investments in securities are subject to market risk. This content is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making investment decisions. For more analysis, visit univest.in\/blogs.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_People_Also_Ask\"><\/span><strong>Frequently Asked Questions (People Also Ask)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_Why_did_Divis_Labs_share_price_fall_today\"><\/span><strong>Q1. Why did Divi&#8217;s Labs share price fall today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Divi&#8217;s fell 5.3% as the global price of Dextromethorphan (DXM) \u2014 one of its key APIs \u2014 fell 22% due to new Chinese manufacturing capacity additions. DXM contributes approximately Rs 800 crore in annual revenue. Combined with Naproxen&#8217;s 8% price decline, Divi&#8217;s Q4 EBITDA margin compressed to 33.8% from 36% year-on-year.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_What_is_DXM_and_why_does_it_matter_for_Divis\"><\/span><strong>Q2. What is DXM and why does it matter for Divi&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Dextromethorphan (DXM) is an API used in cough suppressant medications globally. Divi&#8217;s is one of the world&#8217;s largest DXM manufacturers with world-class cost efficiency. DXM contributes approximately 12% of Divi&#8217;s annual revenue. A 22% price decline reduces Divi&#8217;s quarterly EBITDA by approximately Rs 60 crore \u2014 hence the stock reaction.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_Is_Divis_Labs_a_buy_after_todays_fall\"><\/span><strong>Q3. Is Divi&#8217;s Labs a buy after today&#8217;s fall?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This article does not constitute investment advice. Divi&#8217;s at Rs 4,050 and 34% below its peak offers entry into India&#8217;s best API manufacturer at a meaningful discount. The API price cycle is historically 2\u20134 quarters. The CDMO business is structurally immune to commodity pricing. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_is_Divis_Labs_share_price_target_2026\"><\/span><strong>Q4. What is Divi&#8217;s Labs share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analyst consensus 12-month Divi&#8217;s target is Rs 5,000\u20135,800. The stock trades at Rs 4,050, implying 23\u201343% upside. DXM price recovery and CDMO order book expansion are the primary catalysts. These are analyst estimates, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_What_is_CDMO_and_why_is_it_important_for_Divis\"><\/span><strong>Q5. What is CDMO and why is it important for Divi&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>CDMO (Contract Development and Manufacturing Organisation) services involve manufacturing specific drug molecules for innovator pharmaceutical companies under long-term contracts. Unlike generic APIs \u2014 where prices are set by global supply-demand \u2014 CDMO pricing is fixed per contract.<\/p><p>Divi&#8217;s CDMO revenue of Rs 320 crore in Q4 FY26 is growing 28% annually at 40%+ margins.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q6_How_did_Chinese_overcapacity_affect_Divis_before\"><\/span><strong>Q6. How did Chinese overcapacity affect Divi&#8217;s before?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In FY19-20, Naproxen API prices fell 35% due to Chinese capacity addition. Divi&#8217;s stock fell 28% over 6 months. Within 18 months, prices recovered as new Chinese capacity ran below sustainable cash margins. Divi&#8217;s margin returned to above 35% by FY21. The current DXM cycle is following a structurally similar pattern.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q7_What_is_Divis_competitive_advantage_in_APIs\"><\/span><strong>Q7. What is Divi&#8217;s competitive advantage in APIs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Divi&#8217;s competitive moats: world-class process chemistry talent (25%+ of employees are PhDs\/MScs), lowest-cost API manufacturing globally ($8\u20139\/kg for DXM vs industry average $12\u201315\/kg), zero debt balance sheet, and a clean regulatory track record across all inspected facilities.<\/p><p>These advantages mean Divi&#8217;s survives pricing cycles that eliminate less efficient competitors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q8_What_should_long-term_Divis_investors_do\"><\/span><strong>Q8. What should long-term Divi&#8217;s investors do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Monitor DXM global price monthly \u2014 WuXi AppTec and Huahai Pharmaceutical quarterly earnings provide China-side context. Rs 3,800 is the 52-week low and technical support. CDMO order announcements are the quality signal to watch alongside API prices. Consult a SEBI-registered financial advisor before making investment decisions.<\/p><p>Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions. For more analysis, visit Univest Blogs.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span><strong>Recent Articles<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-krbl-share-price-falling\"><strong>Why is KRBL Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-reliance-infrastructures-share-price-falling\"><strong>Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-mahanagar-gas-share-price-falling\"><strong>Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-happiest-minds-share-price-falling\"><strong>Why is Happiest Minds Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Laboratories \u2014 India&#8217;s most respected API manufacturer and the [Click Here \u2013 Get Free Investment Predictions on Univest] What Triggered the Fall \u2014 Key Details Parameter Detail Trigger Dextromethorphan (DXM) API global price falls 22% QoQ on Chinese capacity addition DXM Revenue (Divi&#8217;s) Approximately Rs 800 Cr annually \u2014 Chinese API Overcapacity 4 new<\/p>\n","protected":false},"author":23,"featured_media":70276,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3848],"class_list":["post-70275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-share-price-fall"],"metadata":{"_edit_lock":["1776076812:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["71"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Divi Laboratories Share Price Falls \u2014 Analysis"],"rank_math_description":["Divi Laboratories share price falls \u2014 Full analysis, price support levels, 3 scenarios and what investors should do."],"rank_math_focus_keyword":["Divi Laboratories"],"_thumbnail_id":["70276"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7936"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13160509\/Divi-s-Laboratories.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70275"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70275\/revisions"}],"predecessor-version":[{"id":70279,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70275\/revisions\/70279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70276"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}